Somatostatin Analogues do not Aff ect Calcium Metabolism in Patients with Acromegaly and Primary Hyperparathyroidism due to MEN 1-Like Syndrome
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Somatostatin Analogues do not Aff ect Calcium Metabolism in Patients with Acromegaly and Primary Hyperparathyroidism due to MEN 1-Like Syndrome ; volume:43 ; number:02 ; year:2010 ; pages:e1-e1
Hormone and metabolic research ; 43, Heft 02 (2010), e1-e1
- Beteiligte Personen und Organisationen
-
Bogazzi, F.
Lombardi, M.
Russo, D.
Sardella, C.
Raggi, F.
Brogioni, S.
Cetani, F.
Ceccarelli, C.
Mariani, G.
Basolo, F.
Martino, E.
- DOI
-
10.1055/s-0030-1268482
- URN
-
urn:nbn:de:101:1-2018102212203925922677
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:29 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Bogazzi, F.
- Lombardi, M.
- Russo, D.
- Sardella, C.
- Raggi, F.
- Brogioni, S.
- Cetani, F.
- Ceccarelli, C.
- Mariani, G.
- Basolo, F.
- Martino, E.
Ähnliche Objekte (12)
Combined treatment of somatostatin analogues with pegvisomant in acromegaly
Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly
Prescription patterns of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
Long-term remission of acromegaly after somatostatin analogues withdrawal: a single-centre experience
The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly
Safety review: Dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
Acromegaly
Differences in somatostatin receptor subtype expression in patients with acromegaly : new directions for targeted therapy?
Differences in somatostatin receptor subtype expression in patients with acromegaly: new directions for targeted therapy?
Aff.
Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients
Piepke goh glatt aff, glatt aff,
Combined treatment of somatostatin analogues with pegvisomant in acromegaly
Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly
Prescription patterns of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
Long-term remission of acromegaly after somatostatin analogues withdrawal: a single-centre experience
The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly
Safety review: Dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
Acromegaly
Differences in somatostatin receptor subtype expression in patients with acromegaly : new directions for targeted therapy?
Differences in somatostatin receptor subtype expression in patients with acromegaly: new directions for targeted therapy?
Aff.
Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients
Piepke goh glatt aff, glatt aff,
Combined treatment of somatostatin analogues with pegvisomant in acromegaly
Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly
Prescription patterns of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
Long-term remission of acromegaly after somatostatin analogues withdrawal: a single-centre experience
The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly
Safety review: Dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
Acromegaly
Differences in somatostatin receptor subtype expression in patients with acromegaly : new directions for targeted therapy?
Differences in somatostatin receptor subtype expression in patients with acromegaly: new directions for targeted therapy?
Aff.
Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients